For the second consecutive year, Yale Cancer Center (YCC) researcher Maximilian Stahl, M.D., was awarded an American Society of Hematology (ASH) Abstract Achievement award.
Besides working at YCC, Stahl is one of five Internal Medicine Traditional Residency Program Chiefs at Yale School of Medicine. He received the ASH award for his abstract titled, “The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with Relapsed and Refractory Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Large, International, Multi-Center Analysis”. The ASH Abstract Achievement Award is a merit-based award for trainees with high-scoring annual meeting abstracts.
The $500 award is intended to support travel to the ASH annual meeting, this year in Atlanta, Georgia, December 9–12. Additionally, Stahl was given the ASH HONORS award (Hematology Opportunities for the Next Generation of Research Scientists).
Under the mentorship of Amer Zeidan, MBBS, Stahl received this award for his abstract titled, “The use of immunosuppressive therapy (IST) in patients with myelodysplastic syndromes (MDS): Clinical outcomes and their predictors in a large international patient cohort”. The ASH HONORS award contributes to the development of the next generation of hematologists by providing research funding for talented residents. In addition to a $5,000 stipend to support work on a hematology-related research project, award recipients attend an orientation breakfast at the ASH annual meeting and attend the Career Development Awards Reception.
About Yale Cancer Center
Yale Cancer Center (YCC) is one of only 49 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in southern New England. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.